Researchers at the University of Arizona have discovered a protein that prevents mosquitoes from hatching, opening the possibility of developing new drugs that could act as birth control for mosquito populations.Continue reading
Category Archives: AZBio News
Flinn Foundation Awards Critical Path Institute and TGen North a New Grant to Develop and Pilot a System to Respond to Antimicrobial Resistance TUCSON, Ariz., January 8
Critical Path Institute (C-Path) and Flagstaff, Arizona-based TGen North — the Pathogen and Microbiome Division of the Translational Genomics Research Institute (TGen) — have received a Phase 1 Concept Validation grant from the Flinn Foundation, of $400,000 over 12 months, to develop and pilot a framework enabling the state institutions to be more responsive to antimicrobial resistance. Working as partners in this venture, C-Path and TGen, an affiliate of City of Hope, will solidify requirements among multiple stakeholders and develop an integrated deployment plan for a statewide Healthcare Associated Antimicrobial Resistant Microbe genomic surveillance system, dubbed Prevent HAARM.Continue reading
Essential nutrient may help fight Alzheimer’s across generations
In a new study, researchers at the Biodesign Institute explore a safe and simple treatment for one of the most devastating and perplexing afflictions: Alzheimer’s disease.Continue reading
Rowpar Pharmaceuticals CEO Shares Insights in Chief Executive Magazine
Jim Ratcliff shares what is like expanding into China during a Trade War.Continue reading
GT Medical Technologies Announces Publication of Data Showing Company’s Targeted Therapy is Effective for Treating Recurrences of Common Type of Brain Tumor
FDA-Cleared GammaTile Therapy Offers New Option for Patients with Recurrent Meningiomas
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
- Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease
- Significantly Expands Phase III Assets with Six Expected Near-Term Product Launches, Representing Greater Than $15 Billion in Revenue Potential
- Registrational Trial Opportunities and Early-Stage Pipeline Position Combined Company for Sustained Leadership Underpinned by Cutting-Edge Technologies and Discovery Platforms
- Strong Combined Cash Flows, Enhanced Margins and EPS Accretion of Greater Than 40% in First Full Year
- Approximately $2.5 Billion of Expected Run-Rate Cost Synergies to Be Achieved by 2022
Xcellerate Biomedical Technologies Announces Half a Million Dollar Raise
Xcellerate Biomedical Technologies, a new company based in Phoenix, AZ, has announced its second round capital raise of $500k for its first line of products, BioXcellerator™ – a medical strength line of formulations sold exclusively through top dermatologists, plastic surgeons, orthopedists and OB/GYN doctors. Continue reading
FDA Releases Final Guidance on the Breakthrough Devices Program
On December 18, 2019, the FDA has issued a final guidance on its Breakthrough Devices Program, which is intended to provide patients and healthcare providers with timely access to medical devices for diagnosis and treatment of life-threatening or irreversibly debilitating conditions and diseases. Continue reading
Critical Path Institute Encouraged by FDA to Move Forward on Type 1 Diabetes Biomarker Initiative
Biomarker potentially could identify individuals at risk of developing T1DContinue reading